The FDA OKs Pfizer-BioNTech Booster For People 65+ Or At High Risk For Severe COVID
A third shot of the vaccine can be given at least six months after the two-dose regimen, according to the authorization. A booster rollout could begin this week.
The Food and Drug Administration authorized a booster dose Wednesday of the Pfizer-BioNTech COVID-19 vaccine for people 65 and older and others at high risk of severe COVID-19.
The FDA says the vaccine can also be given to people ages 18 to 64 whose jobs or institutional exposure to the coronavirus puts them at high risk of serious complications of COVID-19.
A third shot of the vaccine can be given at least six months after.
